文献速递创伤与烧伤重症综合管理与镇静镇痛

大麻对静脉血栓栓塞事件的影响:大麻素使创伤患者形成血栓

Impact of marijuana on venous thromboembolic events: Cannabinoids cause clots in trauma patients.
PubMed 文献 · J Trauma Acute Care Surg · 2020-01-01
一句话结论创伤患者伤前暴露于大麻与静脉血栓栓塞并发症风险升高相关(3.5% vs 1.1%,p=0.03),作者认为需早期识别与治疗。

该研究基于美国外科医师学会创伤质量与改进项目数据库2015—2016年数据,纳入全部成年(≥18岁)创伤患者,按伤前大麻暴露分为THC阳性组与THC阴性组,采用倾向性评分匹配控制人口学、合并症、损伤参数、住院经过及血栓预防用药等混杂因素。匹配后共678例(THC阳性226例 vs THC阴性452例),平均年龄34±15岁,损伤严重度评分14(10-21)。THC阳性组血栓栓塞并发症发生率高于THC阴性组(3.5% vs 1.1%,p=0.03),深静脉血栓(6.6% vs 1.8%,p=0.02)与肺栓塞(2.2% vs 0.2%,p=0.04)发生率亦更高;卒中、心肌梗死与死亡率两组无差异。作者结论认为大麻暴露增加创伤患者血栓栓塞并发症风险,需早期识别与治疗。

要点

  • 创伤患者伤前大麻暴露者血栓栓塞并发症发生率高于无暴露者(3.5% vs 1.1%,p=0.03)。
  • THC阳性组深静脉血栓发生率6.6% vs THC阴性组1.8%(p=0.02),肺栓塞2.2% vs 0.2%(p=0.04)。
  • 卒中(p=0.24)、心肌梗死(p=0.35)与死亡率(p=0.28)两组间无差异。
  • 匹配后两组年龄、性别、损伤严重度评分、脊柱/头/四肢简明损伤定级、普通肝素与低分子肝素使用及住院时长均无差异。
  • 作者认为对伤前大麻暴露的创伤患者需早期识别与治疗血栓栓塞并发症以改善预后。

适用人群与场景

  • 美国外科医师学会创伤质量与改进项目数据库中2015—2016年全部成年(≥18岁)创伤患者。
  • 按伤前大麻暴露分为THC阳性组与THC阴性组,经倾向性评分匹配后纳入678例(THC阳性226例 vs THC阴性452例)。

研究设计与关键结果

  • 研究类型为预后研究,证据等级III级;基于美国外科医师学会创伤质量与改进项目数据库2015—2016年数据,纳入全部成年(≥18岁)创伤患者,按伤前大麻暴露分组并行倾向性评分匹配。
  • 匹配后共678例(THC阳性226例 vs THC阴性452例),平均年龄34±15岁,损伤严重度评分14(10-21)。
  • 两组年龄(p=0.75)、性别(p=0.99)、损伤严重度评分(p=0.54)、脊柱简明损伤定级(p=0.61)、头部简明损伤定级(p=0.32)、四肢简明损伤定级(p=0.38)、普通肝素使用(p=0.54)、低分子肝素使用(p=0.54)及住院时长(p=0.87)均无差异。
  • 总体血栓栓塞并发症发生率为4.3%,死亡率为4%。
  • THC阳性组血栓栓塞并发症发生率高于THC阴性组(3.5% vs 1.1%,p=0.03)。
  • THC阳性组深静脉血栓发生率高于THC阴性组(6.6% vs 1.8%,p=0.02),肺栓塞发生率亦高于THC阴性组(2.2% vs 0.2%,p=0.04)。
  • 卒中(p=0.24)、心肌梗死(p=0.35)与死亡率(p=0.28)两组间无差异。

证据类型、等级与局限

  • 证据类型:预后研究,证据等级III级。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,大麻暴露增加创伤患者血栓栓塞并发症风险;对这一高危创伤患者亚组需早期识别与治疗血栓栓塞并发症以改善预后。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Tetrahydrocannabinoids (THC) can modulate the coagulation cascade resulting in hypercoagulability. However, the clinical relevance of these findings has not been investigated. The aim of our study was to evaluate the impact of preinjury marijuana exposure on thromboembolic complications (TEC) in trauma patients.

METHODS: We performed a 2-year (2015-2016) analysis of American College of Surgeons Trauma Quality and Improvement Program database and included all adult (≥18 year) trauma patients. Patients were stratified based on preinjury exposure to Marijuana: THC + ve and THC -ve groups. We performed propensity score matching to control for confounding variables: demographics, comorbidities, injury parameters, hospital course, and thromboprophylaxis use. Outcomes were TEC (deep venous thrombosis, pulmonary embolism, stroke, myocardial infarction) and mortality.

RESULTS: Of 593,818 trauma patients, 678 patients were matched (THC + ve: 226 vs. THC -ve: 452). Mean age was 34 ± 15 years, Injury Severity Score was 14 (10-21). There was no difference between the two groups regarding age (p = 0.75), sex (p = 0.99), Injury Severity Score (p = 0.54), spine Abbreviated Injury Scale (AIS) (p = 0.61), head AIS (p = 0.32), extremities AIS (p = 0.38), use of unfractionated heparin (p = 0.54), use of low molecular weight heparin (p = 0.54), and hospital length of stay (p = 0.87). Overall, the rate of TEC was 4.3% and mortality was 4%. Patients in THC + ve group had higher rates of TEC compared with those in THC -ve group (3.5% vs. 1.1%, p = 0.03). The rate of deep venous thrombosis (6.6% vs. 1.8%, p = 0.02) and PE (2.2% vs. 0.2%, p = 0.04) was higher in THC + ve group. However, there was no difference regarding the rate of stroke (p = 0.24), myocardial infarction (p = 0.35) and mortality (p = 0.28).

CONCLUSION: THC exposure increases the risk of TEC in patients with trauma. Early identification and treatment for TEC is required to improve outcomes in this high-risk subset of trauma patients.

LEVEL OF EVIDENCE: Prognostic study, level III.

来源:J Trauma Acute Care Surg,查看原文。版权归原作者所有。

参考来源

  1. Stupinski J, Bible L, Asmar S, et al. Impact of marijuana on venous thromboembolic events: Cannabinoids cause clots in trauma patients. J Trauma Acute Care Surg. 2020. PMID: 32209959. doi:10.1097/TA.0000000000002667

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。